CAI Caris Life Sciences, Inc.
Services-Medical Laboratories · Nasdaq · SEC CIK 2019410 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY61.5%
TTM net income YoY151.4%
TTM EPS YoY125.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin13.4%
Net margin9.2%
FCF margin2.8%
EBITDA margin15.5%
Returns
ROE17.2%
ROA8.6%
ROIC (approx.)24.3%
Asset turnover0.94x
Leverage & solvency
Liabilities / assets49.1%
Debt / equity0.61x
Current ratio6.71x
Interest coverage3.28x
Cash quality & payout
Operating cash flow / net income0.87x
Accruals ratio1.1%
Payout ratio—
Capex / revenue5.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $275.36M | $263.71M | $216.17M | $292.89M | $216.83M | $181.40M | $120.92M | $129.91M |
| R&D expense | $33.84M | $32.36M | $31.32M | $31.84M | $21.62M | $25.05M | $23.07M | $27.11M |
| SG&A expense | $69.28M | $66.55M | $59.71M | $56.51M | $51.97M | $64.37M | $52.12M | $43.11M |
| Operating income | $19.32M | $26.93M | $5.28M | $88.41M | $32.64M | -$17.99M | -$57.95M | -$37.05M |
| Interest expense | $9.25M | $9.23M | $12.81M | $11.36M | $13.51M | $19.21M | $12.78M | $13.26M |
| Pretax income | $16.87M | -$614,000 | -$644,000 | $81.96M | $24.32M | -$71.79M | -$102.58M | -$36.95M |
| Income tax | $1.62M | $23,000 | -$134,000 | $0 | $0 | $0 | $0 | $0 |
| Net income | $15.25M | -$637,000 | -$510,000 | $81.96M | $24.32M | -$71.79M | -$102.58M | -$36.95M |
| EBITDA | $25.92M | $33.43M | $10.35M | $92.70M | $37.54M | -$11.59M | -$50.91M | -$27.98M |
| EPS (basic) | 0.05 | 0.00 | 0.00 | — | 0.09 | -7.97 | -3.57 | — |
| EPS (diluted) | 0.05 | 0.00 | 0.00 | — | 0.08 | -7.97 | -3.57 | — |
| Weighted avg. shares (diluted) | 295.14M | 282.89M | 282.56M | — | 297.21M | 64.92M | 35.62M | — |
| Balance sheet | ||||||||
| Cash & equivalents | — | — | $819.90M | $796.27M | $753.22M | $718.93M | $31.20M | $63.95M |
| Short-term investments | $102.06M | $102.20M | $2.31M | $2.29M | $2.27M | $2.25M | — | $2.20M |
| Receivables | $133.32M | $116.89M | $90.52M | $112.14M | $26.70M | $50.89M | — | $88.24M |
| Current assets | $1.07B | $1.06B | $1.01B | $997.80M | $854.25M | $833.32M | — | $215.73M |
| PP&E, net | $102.30M | $95.72M | $82.67M | $63.17M | $64.00M | $61.31M | — | $67.82M |
| Goodwill | $19.34M | $19.34M | $19.34M | $19.34M | $19.34M | $19.34M | — | $19.34M |
| Total assets | $1.26B | $1.23B | $1.16B | $1.13B | $984.57M | $955.06M | — | $343.73M |
| Current liabilities | $158.95M | $191.44M | $143.90M | $127.14M | $86.03M | $90.18M | — | $165.42M |
| Short-term debt | $89,000 | $178,000 | $173,000 | $169,000 | $164,000 | $95,000 | — | $60.09M |
| Long-term debt | $393.18M | $392.97M | $381.40M | $378.82M | $376.30M | $373.61M | — | $319.44M |
| Total debt | $393.27M | $393.15M | $381.57M | $378.99M | $376.46M | $373.71M | — | $379.53M |
| Total liabilities | $616.14M | $637.89M | $568.90M | $548.36M | $506.21M | $502.15M | — | $620.92M |
| Shareholders' equity | $639.48M | $591.73M | $593.49M | $577.31M | $478.36M | $452.90M | -$2.60B | -$2.50B |
| Net debt | — | — | -$438.33M | -$417.28M | -$376.76M | -$345.23M | — | $315.58M |
| Shares outstanding | 286.72M | 282.58M | 282.65M | 282.53M | 282.10M | 281.09M | — | 36.50M |
| Cash flow statement | ||||||||
| Operating cash flow | -$22.25M | $28.48M | $32.88M | $44.78M | $62.42M | $7.29M | -$31.34M | -$38.92M |
| Capital expenditure | $17.47M | $22.07M | $10.34M | $5.09M | $7.09M | $1.39M | $2.69M | $2.29M |
| Free cash flow | -$39.72M | $6.40M | $22.53M | $39.69M | $55.33M | $5.90M | -$34.03M | -$41.21M |
| Investing cash flow | -$17.47M | -$122.19M | -$10.34M | -$5.09M | -$7.09M | -$1.39M | -$2.69M | -$2.29M |
| Financing cash flow | $14.23M | -$36.90M | $824,000 | $3.40M | -$21.10M | $681.40M | $1.28M | $226,000 |
| Depreciation & amortization | $6.60M | $6.50M | $5.07M | $4.29M | $4.90M | $6.40M | $7.04M | $9.07M |
| Stock-based compensation | $18.50M | $22.22M | $15.87M | $13.37M | $13.65M | $28.29M | $14.69M | $4.98M |
| Share buybacks | $10.01M | $21.36M | $0 | $91,000 | $0 | $0 | $22,000 | $0 |
Free plan shows the latest 8 periods; Pro shows all 10 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.